JP2022532868A - Ｃｄ１２３結合性ポリペプチド及びその使用 - Google Patents

Ｃｄ１２３結合性ポリペプチド及びその使用 Download PDF

Info

Publication number
JP2022532868A
JP2022532868A JP2021564745A JP2021564745A JP2022532868A JP 2022532868 A JP2022532868 A JP 2022532868A JP 2021564745 A JP2021564745 A JP 2021564745A JP 2021564745 A JP2021564745 A JP 2021564745A JP 2022532868 A JP2022532868 A JP 2022532868A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
acid sequence
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564745A
Other languages
English (en)
Japanese (ja)
Inventor
チェルシー マセド
カイル ジョーンズ
ウィリアム クラゴ
アンドリュー ホーランド
ミルトン マー
ジョン シー． ティマー
ブレンダン ピー． エッケルマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inhibrx Inc
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of JP2022532868A publication Critical patent/JP2022532868A/ja
Priority to JP2024231707A priority Critical patent/JP2025060941A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021564745A 2019-05-04 2020-05-01 Ｃｄ１２３結合性ポリペプチド及びその使用 Pending JP2022532868A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024231707A JP2025060941A (ja) 2019-05-04 2024-12-27 Ｃｄ１２３結合性ポリペプチド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843407P 2019-05-04 2019-05-04
US62/843,407 2019-05-04
PCT/US2020/030968 WO2020227071A1 (en) 2019-05-04 2020-05-01 Cd123-binding polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024231707A Division JP2025060941A (ja) 2019-05-04 2024-12-27 Ｃｄ１２３結合性ポリペプチド及びその使用

Publications (1)

Publication Number Publication Date
JP2022532868A true JP2022532868A (ja) 2022-07-20

Family

ID=70740820

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564745A Pending JP2022532868A (ja) 2019-05-04 2020-05-01 Ｃｄ１２３結合性ポリペプチド及びその使用
JP2024231707A Pending JP2025060941A (ja) 2019-05-04 2024-12-27 Ｃｄ１２３結合性ポリペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024231707A Pending JP2025060941A (ja) 2019-05-04 2024-12-27 Ｃｄ１２３結合性ポリペプチド及びその使用

Country Status (7)

Country Link
US (2) US11434297B2 (enExample)
EP (1) EP3966242A1 (enExample)
JP (2) JP2022532868A (enExample)
CN (2) CN114040926B (enExample)
AU (1) AU2020269268A1 (enExample)
CA (1) CA3139061A1 (enExample)
WO (1) WO2020227071A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
JP7013754B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
JP2020151570A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
JP6879413B2 (ja) * 2020-06-24 2021-06-02 株式会社三洋物産 遊技機
WO2022099175A1 (en) * 2020-11-09 2022-05-12 2Seventy Bio, Inc. Cd33 targeted immunotherapies
EP4294829A4 (en) * 2021-02-17 2025-03-19 IGM Biosciences Inc. ANTI-CD123 BINDING MOLECULES AND THEIR USES
US20240141071A1 (en) * 2021-02-26 2024-05-02 LAVA Therapeutics N.V. Antibodies that bind cd123 and gamma-delta t cell receptors
JP2021079226A (ja) * 2021-03-01 2021-05-27 株式会社三洋物産 遊技機
JP2021079225A (ja) * 2021-03-01 2021-05-27 株式会社三洋物産 遊技機
JP2021087833A (ja) * 2021-03-01 2021-06-10 株式会社三洋物産 遊技機
JP2021087836A (ja) * 2021-03-01 2021-06-10 株式会社三洋物産 遊技機
IL309957A (en) 2021-07-14 2024-03-01 2Seventy Bio Inc Engineered t cell receptors fused to binding domains from antibodies
KR20250008809A (ko) 2022-04-08 2025-01-15 리제너론 파마슈티칼스 인코포레이티드 다분할 수용체 및 신호전달 복합체
JP7556434B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
JP7556433B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
JP7556432B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
CN115724972B (zh) * 2022-09-06 2024-08-20 河北森朗生物科技有限公司 抗cd123的纳米抗体、嵌合抗原受体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018091606A1 (en) * 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018102795A2 (en) * 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2330201B1 (en) 2003-10-22 2017-04-05 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
WO2015017214A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
WO2015044386A1 (en) 2013-09-26 2015-04-02 Ablynx Nv Bispecific nanobodies
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
KR20180042361A (ko) 2015-08-24 2018-04-25 셀렉티스 통합된 통제가능한 기능들을 가진 키메라 항원 수용체들
UA122079C2 (uk) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
EP3387014B1 (en) * 2015-12-11 2022-01-19 Leadartis, S.L. Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
IL265484B1 (en) * 2016-09-21 2025-09-01 Aptevo Res & Development Llc Cd123 binding proteins and related compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018091606A1 (en) * 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018102795A2 (en) * 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof

Also Published As

Publication number Publication date
WO2020227071A1 (en) 2020-11-12
US20200347142A1 (en) 2020-11-05
AU2020269268A1 (en) 2021-11-11
US20230065306A1 (en) 2023-03-02
CN114040926A (zh) 2022-02-11
US11919963B2 (en) 2024-03-05
CA3139061A1 (en) 2020-11-12
JP2025060941A (ja) 2025-04-10
CN114040926B (zh) 2025-07-29
EP3966242A1 (en) 2022-03-16
CN121021694A (zh) 2025-11-28
US11434297B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
JP7789002B2 (ja) Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
JP2022532868A (ja) Ｃｄ１２３結合性ポリペプチド及びその使用
JP7571347B2 (ja) ＣＬＥＣ１２ａ結合性ポリペプチド及びその使用
TWI863932B (zh) 5t4單域抗體及其治療性組合物
JP2022516557A (ja) 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
JP2022512684A (ja) Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物
JP2022504822A (ja) Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
JP7525510B2 (ja) Ｃｄ３３結合性ポリペプチド及びその使用
TW201718630A (zh) 多價和多重特異性之結合ｇｉｔｒ的融合蛋白
JP2023532904A (ja) 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
JP2021533761A (ja) Ｏｘ４０結合性ポリペプチド及びその使用
TW202328171A (zh) 靶向NKp46之經修飾之IL-2多肽及其用途
EA046221B1 (ru) Cd33-связывающие полипептиды и их применение
EA046257B1 (ru) Clec12a-связывающие полипептиды и их применение

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240903

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240925